Spruce Biosciences Appoints Camilla V. Simpson to Board of Directors

Simpson brings 22 years of industry experience to Spruce, a clinical-stage biotech developing a novel treatment for congenital adrenal hyperplasia, a rare endocrine disease SAN FRANCISCO, Nov. 13, 2017 -- (Healthcare Sales & Marketing Network) -- Spruc... Biopharmaceuticals, Personnel Spruce Biosciences, adrenal hyperplasia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news